Medical device firm NeuroMetrix is planning to unveil its new wearable pain relief device, Quell, in January 2015.
It will be unveiled at the International Consumer Electronics Show (CES) in Las Vegas, US.
Go deeper with GlobalData
Quell is designed for consumers looking for non-pharmacological pain control options.
Featuring the company’s non-invasive neurostimulation technology, the device will provide relief from chronic pain, specifically neuropathic pain that result due to diabetes and lower back problems.
The company said this advanced lightweight wearable device can be worn during the day while active and at night while sleeping.
The device was cleared by US Food and Drug Administration (FDA) to treat chronic pain without a prescription. Users of this device will also have the option of using their smartphone to automatically track and personalise their pain therapy.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataNeuroMetrix president Shai Gozani said: "We are excited to be on the cusp of entering the $4bn US over-the-counter pain relief market.
"We believe that as advanced wearable therapeutic technology, Quell represents a new pain relief category that will be attractive to consumers looking for non-pharmacological pain control options."
The company expects to make the device commercially available for customers in the second quarter of 2015.
NeuroMetrix develops wearable medical technology and point-of-care tests for patients and physicians to better manage chronic pain, nerve diseases and sleep disorders.
Image: Quell, wearable pain relief device. Photo: courtesy of Business Wire / NeuroMetrix.
